Quality of life in heart failure patients may be improved with Canagliflozin category
Advertisement
The CHIEF- HF trial results have shown that treating heart failure (HF) patients with canagliflozin a sodium-glucose cotransporter 2 (SGLT2) inhibitor, significantly improves quality of life. Canagliflozin is currently approved for glycemic control in patients with type 2 diabetes.
It is also approved for the treatment of diabetic kidney disease and to reduce the risk of HF hospitalizations in patients with type 2 diabetes. It also gained an indication for the reduction of major adverse cardiovascular events in patients with type 2 diabetes and an increased risk of atherosclerotic cardiovascular disease.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.